• admin@condrug.com
  • Mon - Sat: 8.00 am - 7.00 pm

We develop solutions for your clinical data needs

Linkedin-in Link
ConDrug
  • Workspace
  • Drug Safety Data
  • Blog
  • About Us
  • Contacts

Whatsapp

+1 (877) 703-6664

Free to Use
ConDrug
  • Workspace
  • Drug Safety Data
  • Blog
  • About Us
  • Contacts

Blog

Pharmacovigilance

AI in Pharmacovigilance: How Artificial Intelligence Is Transforming Drug Safety

Discover how AI-driven pharmacovigilance is revolutionizing drug safety by transforming adverse event detection, enabling intelligent signal detection, and powering proactive safety surveillance with NLP and machine learning—alongside the key risks, ethics, and regulatory considerations.

Protein-Peptide Drugs

Tirzepatide for Type 2 Diabetes: Dual Incretin “Twincretin” Therapy, Benefits & Weight Loss

Discover how tirzepatide’s dual GIP/GLP-1 “twincretin” mechanism transforms type 2 diabetes treatment. Learn about its powerful HbA1c reduction, significant weight loss, cardiometabolic benefits, and once-weekly peptide design.

New Drugs

Mirdametinib and Depression: How MEK Inhibition Could Transform Treatment-Resistant Mood Disorders

Discover how mirdametinib, a next-generation MEK1/2 inhibitor originally developed for MAPK-driven tumors, is emerging as a promising tool to modulate ERK signaling, improve synaptic plasticity, and potentially treat treatment-resistant depression beyond traditional monoamine-based antidepressants.

Small Molecule Drugs

Molecular Glue Degraders in Oncology: Turning “Undruggable” Cancer Targets into Therapies

Discover how molecular glue degraders harness the ubiquitin–proteasome system to destroy oncogenic proteins once considered “undruggable.” Learn what molecular glues are, how they differ from traditional inhibitors, and why they’re poised to transform precision oncology.

Pharmacovigilance
Abstract illustration of artificial intelligence analyzing medical and drug safety data for modern pharmacovigilance

AI in Pharmacovigilance: How Machine Learning Is Transforming Drug Safety Monitoring

Discover how AI and machine learning are revolutionizing pharmacovigilance, from faster signal detection and automated case processing to improved data quality and proactive drug safety monitoring.

New Drugs

Novelmab in Oncology: How This Next‑Generation Bispecific Antibody Targets PD‑1 and Solid Tumors

Discover what Novelmab is, how its dual targeting of PD‑1 and a tumor‑associated antigen works, and why this next‑generation bispecific antibody is generating buzz in oncology for potentially overcoming resistance to standard immunotherapy in solid tumors.

Protein-Peptide Drugs

What Is Semaglutide? How This GLP‑1 Peptide Works for Weight Loss and Metabolic Health

Learn what semaglutide is, how this GLP‑1 receptor agonist works in the pancreas, stomach, and brain, and why it’s transforming obesity, weight loss, and type 2 diabetes treatment with bariatric surgery–level results.

Small Molecule Drugs

AI-Designed Small Molecule Drugs: How Machine Learning Is Transforming Drug Discovery

Discover how AI-designed small molecule drugs are reshaping drug discovery. Learn how deep learning, generative models, and structure-based machine learning accelerate target-specific molecule design, optimize ADMET, and compress early discovery timelines from years to months.

Pharmacovigilance

AI in Pharmacovigilance: Transforming Drug Safety with Continuous Intelligence

Discover how AI and machine learning are revolutionizing pharmacovigilance by automating case intake, enabling continuous safety surveillance, and improving drug risk detection across the product life cycle while meeting regulatory expectations.

New Drugs

What Is Tirzepatide? Dual GIP/GLP‑1 Agonist for Type 2 Diabetes and Weight Loss

Learn what tirzepatide is, how its dual GIP and GLP‑1 receptor agonism works, and why clinical trials show unprecedented benefits for blood sugar control and weight loss in type 2 diabetes.

  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 20
  • 21
  • 22
Categories
  • New Drugs (53)
  • Pharmacovigilance (73)
  • Protein-Peptide Drugs (41)
  • Small Molecule Drugs (45)
Tags
adverse drug reactions adverse event detection AI in drug safety AI in Healthcare AI in Pharmacovigilance artificial intelligence deucravacitinib drug discovery Drug Safety GIP GIP GLP-1 dual agonist GLP-1 GLP-1 agonist healthcare AI healthcare data incretin therapy Life Sciences Machine Learning machine learning in healthcare machine learning in pharma] metabolic disease metabolic health migraine treatment NLP obesity treatment peptide therapeutics pharmacovigilance pharmacovigilance automation PROTACs real-world data] real-world evidence signal detection small molecule design small molecule drugs SURPASS trials targeted protein degradation tirzepatide TYK2 inhibitor type 2 diabetes type 2 diabetes treatment weight loss weight loss drugs weight loss medication [AI drug discovery [AI pharmacovigilance
Recent Posts
  • Gefapixant for Chronic Cough: How This P2X3 Antagonist Is Changing Treatment
    17/12/2025
  • What Is Retatrutide? Triple Agonist Weight Loss Drug Explained (GLP‑1, GIP, Glucagon)
    17/12/2025
  • Ensifentrine for COPD: Dual PDE3/4 Inhibitor Mechanism, Benefits & Clinical Data
    17/12/2025
  • Home
  • Workspace
  • Contacts

Copyright © 2026 ConDrug All Rights Reserved.

Linkedin-in Handshake